2 weeks Ago By Defense World Staff
Genfit S.A. ( EPA:GNFT – Get Free Report )’s stock price was down 2.
9% on Tuesday . The company traded as low as €3.95 ($4.
16) and last traded at €3.98 ($4.19).
Approximately 239,671 shares traded hands during mid-day trading, The stock had previously closed at €4.10 ($4.32).
Genfit Price Performance The firm has a 50 day moving average of €4.88 and a 200-day moving average of €4.30.
Genfit Company Profile ( Get Free Report ) Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Further Reading Five stocks we like better than Genfit What Are Dividend Contenders? Investing in Dividend Contenders Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor What Does a Gap Up Mean in Stocks? How to Play the Gap Why Warren Buffett Is Selling: A Look at His Latest Market Moves What is Put Option Volume? Why Amazon Shares May Never Trade Below $200 Again Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter ..
